Therapeutic Antibodies Against Prion Diseases From PRNP Mutation Carriers

Prion Diseases Clinical Trial

— PRNP  

Official title:

Therapeutic Antibodies Against Prion Diseases From PRNP Mutation Carriers

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02837705
• Other study ID #: 2015-0514
• Status: Completed
• Start date: September 1, 2015
• Est. completion date: March 1, 2019

Study information

• Verified date: May 2023
• Source: University of Zurich
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

The human Prion diseases can be classified into sporadic, acquired and inherited forms. Inherited forms usually manifest in higher age so there have to be factors preventing Prion propagation in young mutation carriers. Antibodies against the flexible tail of Prions have been shown to be protective in mice. The investigators intend to screen mutation carriers and controls for the presence of Prion autoantibodies.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 213
• Est. completion date: March 1, 2019
• Est. primary completion date: October 15, 2018
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 1 Year to 99 Years

Eligibility

Inclusion Criteria:

• Relatives of patients of genetic Prion diseases
• Obtained informed consent

Exclusion Criteria:

• No informed consent

Related Conditions & MeSH terms

• Prion Diseases

Intervention

Other:
• blood draw

Locations

Country	Name	City	State
Austria	Medical University Graz	Graz
Germany	University Medical Center Göttingen	Göttingen
Israel	CJD Foundation Israel	Pardés H_anna Karkur
Italy	Istituto di Ricerche Farmacologiche	Milano
Slovakia	Slovak Medical University	Bratislava
Switzerland	Institute of Neuropathology	Zürich
United States	UCSF Memory and Aging Center	San Francisco	California

Sponsors (1)

Lead Sponsor	Collaborator
University of Zurich

Countries where clinical trial is conducted

United States,  Austria,  Germany,  Israel,  Italy,  Slovakia,  Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Anti-Prion protein autoantibody levels		Baseline, up to 90 years